Journey Medical (NASDAQ:DERM) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Journey Medical (NASDAQ:DERM) posted its quarterly earnings results on Wednesday. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02, FiscalAI reports. Journey Medical had a negative return on equity of 51.42% and a negative net margin of 18.48%.The company had revenue of $16.08 million for the quarter, compared to analysts’ expectations of $18.86 million.

Here are the key takeaways from Journey Medical’s conference call:

• EMROSI achieved ~53,000 prescriptions in nine months, Q4 scripts rose ~50% sequentially, and >3,500 unique prescribers drove an exit annualized run-rate above 126,000 scripts.
• Full‑year 2025 revenue was $61.9M (+10%), gross margin improved to 66.2%, GAAP net loss narrowed to $11.4M, and the company reported positive adjusted EBITDA of $2.9M while ending the year with ~$24.1M cash.
• Market access is progressing—~100 million commercial covered lives and contracts with two of the top three GPOs (third expected soon)—but downstream payer formulary timing means prescription demand currently outpaces recognized revenue.
• Legacy products, notably the Accutane franchise, faced pressure from generic competition, weighing on the base business revenue in 2025.
• Management expects to remain adjusted EBITDA positive in 2026, plans a modest salesforce increase and the launch of one to two additional dermatology products, and sees reimbursement gains as the key driver of revenue conversion this year.

Journey Medical Price Performance

Journey Medical stock traded down $0.18 during midday trading on Friday, reaching $4.61. 200,361 shares of the stock traded hands, compared to its average volume of 174,684. The stock has a market cap of $153.15 million, a P/E ratio of -9.80 and a beta of 0.81. The stock’s fifty day moving average is $8.00 and its 200-day moving average is $7.80. The company has a quick ratio of 1.12, a current ratio of 1.42 and a debt-to-equity ratio of 0.75. Journey Medical has a 12 month low of $4.51 and a 12 month high of $9.56.

Key Journey Medical News

Here are the key news stories impacting Journey Medical this week:

• Positive Sentiment: Q4 EPS beat — Journey reported adjusted EPS of -$0.04 vs. consensus -$0.06, showing better-than-expected profitability improvement for the quarter. Earnings Call Transcript
• Positive Sentiment: Emrosi commercial ramp — Management highlighted Emrosi™ momentum: Emrosi generated meaningful net revenues in FY2025 ( ~$14.7M full‑year after its launch), ~53,000 prescriptions filled and payer access covering 100M+ commercial lives — supporting a path to EBITDA improvement. Emrosi Coverage & EBITDA Growth
• Positive Sentiment: HC Wainwright reiterates Buy with $13 target — The firm kept a Buy rating and $13 price objective (large upside from current levels), signaling analyst confidence in longer-term upside despite near-term variability. HC Wainwright Coverage
• Neutral Sentiment: Corporate disclosure — Full FY2025 results, press release and the investor call transcript are available for review for detailed line‑item and guidance commentary. Press Release & Results
• Negative Sentiment: Revenue missed estimates — Q4 revenue was $16.08M versus consensus ~$18.86M, a shortfall that underscores pacing risk in top‑line recovery and likely drove some intraday selling. Key Metrics vs Estimates
• Negative Sentiment: Analyst model cuts — HC Wainwright trimmed FY2026–FY2030 EPS projections slightly across multiple years (small downgrades to multi‑year targets), which can reduce near‑term sentiment even though the rating remains Buy. Analyst Estimate Changes
• Negative Sentiment: Profitability metrics still negative — Journey reported a negative net margin (~-18.5%) and negative ROE (~-51%), signaling the company remains unprofitable overall despite operational progress. Financial Results

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE raised its holdings in shares of Journey Medical by 4,707.0% in the second quarter. Bank of America Corp DE now owns 4,134 shares of the company’s stock worth $30,000 after buying an additional 4,048 shares during the period. Raymond James Financial Inc. purchased a new position in Journey Medical during the 2nd quarter valued at $36,000. JPMorgan Chase & Co. purchased a new stake in Journey Medical in the second quarter worth $41,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Journey Medical in the second quarter worth $48,000. Finally, Russell Investments Group Ltd. bought a new stake in shares of Journey Medical during the third quarter worth $61,000. 7.25% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

DERM has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Journey Medical in a research report on Wednesday, January 21st. HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Journey Medical in a research note on Thursday. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $13.00.

About Journey Medical

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.